Vaccine Researchers Face Unique Challenges in Updating New Covid Boosters

Apr 18, 2022 | Publications

Click here to view...

HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission

Apr 5, 2022 | Press Releases

HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections Seattle, WA, (April 5, 2022) – HDT Bio Corp.,...

HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine

Mar 29, 2022 | Press Releases

HDT’s technology offers simpler manufacturing, easier deployment, and requires much lower doses than existing COVID-19 RNA vaccines, enabling global supply.  Vaccine targets Beta variant; has demonstrated effectiveness against other variants;  will be evaluated as...

Spectrum News: The Quest is On for a “Universal” COVID-19 Vaccine, Is it Possible?

Mar 27, 2022 | In the News

Click here to view...

Clinical Trials Arena: HDT Bio dose first subjects in Phase I Covid-19 vaccine trial

Jan 19, 2022 | In the News

Click here to view...